Excel C Capsule 3 Milligrams (Rivastigmine Tartrate)

Adult dose

Administration: Rivastigmine is administered orally twice daily, with the morning and evening meals. ○ Adults: 1. Treatment of mild to moderate dementia of the Alzheimer type The initial dose is 3 mg of rivastigmine per day. For each patient, increase the dose at intervals of at least 2 weeks to the highest tolerated dose or the maximum recommended dose of 12 mg per day. Because clinical trials showed greater efficacy at doses of 6 mg per day and above, a target dose range of 6~12 mg per day is recommended for most patients. Recommended dose titration schedule Administer 1.5mg per dose twice daily for at least 2 weeks. If well tolerated, the dose may be increased to 3mg twice daily. Subsequent increases may be made to 4.5mg per dose twice daily and, if well tolerated, after at least 2 weeks, to 6mg per dose twice daily. If adverse reactions (e.g., nausea, vomiting, abdominal pain, or loss of appetite) or weight loss occurs, one or more doses may be omitted. However, if adverse reactions or weight loss persist, reduce the daily dose to the previously well-tolerated dose. 2. Treatment of mild to moderate dementia associated with Parkinson's disease In controlled clinical trials in patients with dementia associated with Parkinson's disease, rivastigmine was administered at 3~12mg per day in 2 divided doses. (1.5~6mg per dose twice daily.) The initial dose is 1.5mg per dose twice daily. At intervals of at least 4 weeks between doses, subsequent doses may be increased according to the patient's tolerability to 3mg per dose twice daily, then to 4.5mg per dose twice daily, and subsequently to 6mg per dose twice daily. If adverse reactions (e.g., nausea, vomiting, abdominal pain, or loss of appetite), weight gain, or extrapyramidal symptoms (e.g., tremor) occur during treatment, omitting one or more doses may reduce these symptoms. If adverse reactions persist, the daily dose may be temporarily reduced to the previously well-tolerated dose, or discontinuation of treatment may be considered. 3. Maximum recommended dose Administer 6 mg per dose orally twice daily. 4. Resumption of treatment The incidence and severity of adverse reactions generally increase at higher doses. If treatment is interrupted for more than 3 days, restart at the lowest daily dose and titrate as described above. ○ Patients with hepatic or renal impairment: 1. Exposure is increased in patients with moderate renal impairment and mild to moderate hepatic impairment, and more adverse reactions may occur. Therefore, take particular care when titrating the dose according to individual tolerability. 2. Do not administer to patients with severe hepatic impairment, as no studies have been conducted in these patients.

Child dose

This medicine has not been studied in children; therefore, its use in children is not recommended.

This medication should not be used in patients with allergies to specific ingredients or severe liver impairment. Caution should be exercised when administering to patients with heart diseases, gastric ulcers, asthma, urinary retention, seizures, or extrapyramidal disorders. While taking this medication, gastrointestinal symptoms such as nausea, vomiting, and diarrhea may occur, particularly during dose adjustments when these symptoms may be more prevalent. There may be neurological adverse reactions such as dizziness, headache, drowsiness, and tremors, so caution is needed. Cardiac issues such as bradycardia or arrhythmias may arise, necessitating careful observation of heart conditions. This medication can worsen symptoms of Parkinson's disease, so patients with Parkinson's disease should exercise particular caution. Weight loss may occur, so it is important to regularly monitor the patient's weight during treatment. Drug interactions may occur when used with other cholinergic or anticholinergic medications, so care should be taken when co-administering. When undergoing anesthesia, this medication should be discontinued for a certain period, and when stopping or resuming the dosage, it should be gradually adjusted to reduce side effects like vomiting. The safety of this medication during pregnancy or breastfeeding has not been adequately established, so it should be used cautiously after consulting a physician. Safety and efficacy in pediatric patients have not been established, so usage is not recommended. In case of overdose, symptoms such as nausea, vomiting, bradycardia, and confusion may occur, and severe cases require immediate medical attention. This medication should be stored out of reach of children and not transferred to another container.

• Nausea
• vomiting
• urinary tract infection
• agitation
• confusion
• nightmares
• anxiety
• insomnia
• depression
• hallucination

This medication may be sensitive to air or moisture, so it should be stored in a sealed container. It is advisable to maintain a storage temperature between 1 to 30 degrees Celsius. This will help preserve the medication's efficacy and safety over a long period.

Appearance

A hard capsule filled with a white to off-white powder, with light brown upper and lower parts.

Package unit

30 capsules (10 capsules/PTP x 3)